The 2025 edition of the Chinese Pharmacopoeia, implemented on October 1st, introduces substantial upgrades to hollow capsule quality standards. Three core revisions-targeting brittleness, microbial control, and residue detection-have significantly raised industry quality thresholds, driving technological advancements and safety improvements across the supply chain.
1. Brittleness Requirement: Enhanced Mechanical Strength Standards
The brittleness limit, a key indicator of capsule durability closely monitored by pharmaceutical manufacturers, has been tightened to unprecedented levels:
Revised Criterion: The maximum allowable number of broken capsules in brittleness tests has been reduced from ≤5 to ≤2 .
Technical Complement: A new 30mm specification test tube has been added to ensure accurate detection of large-size capsules, addressing the growing demand for exported large-diameter products .
Rationale & Impact: This revision responds to two critical industry needs: (1) the high mechanical strength requirements of Chinese patent medicines and low-moisture formulations, which tend to exacerbate capsule brittleness; and (2) stricter international standards for exported capsules . For manufacturers, this mandates upgrades in raw material selection (e.g., high-purity gelatin or HPMC) and process precision-such as optimizing dip-coating thickness uniformity and mold temperature control-to reduce breakage rates. Notably, leading enterprises like Kailai Capsule had already adopted ≤2 broken capsules as their internal control standard, aligning with the new pharmacopoeia requirements .
2. Microbial Control: Stringent Environmental Humidity and Detection Rules
Microbial limit management has been strengthened through both environmental control and testing protocol revisions:
Humidity Mandate: Production environments must maintain relative humidity below 30% to inhibit mold growth . This specification is scientifically grounded in moisture activity (aw) principles: molds require a minimum aw of 0.75–0.85 for growth, and controlling humidity below 30% effectively reduces free water in capsules, lowering aw to levels that suppress microbial proliferation .
Testing Upgrades: The pharmacopoeia now reinforces requirements for media suitability validation and colony counting principles. For aerobic microbial count testing, dilutions yielding ≤250 CFU are preferred, while ≤50 CFU dilutions are recommended for mold/yeast counts to ensure result accuracy .
Industry Implications: Manufacturers must invest in high-efficiency dehumidification systems and real-time humidity monitoring tools. For example, enterprises in Zhejiang Xinchang have integrated "capsule cloud MES 2.0" systems to track environmental parameters, ensuring compliance with the 30% humidity limit . This revision is particularly critical for traditional Chinese medicine capsules, which historically face higher microbial contamination risks due to complex raw material compositions .
3. Residue Detection: Simultaneous Analysis of Ethylene Oxide and 2-Chloroethanol
A groundbreaking revision in residue testing combines efficiency and sensitivity, addressing safety concerns associated with sterilization byproducts:
New Detection Scope: Simultaneous testing for ethylene oxide (EO) and 2-chloroethanol residues is now mandatory, using headspace gas chromatography with flame ionization detection .
Performance Leap: The integrated method boosts detection efficiency by 50% compared to separate testing protocols and improves sensitivity by 10-fold . This is enabled by advanced GC-FID features, including precise temperature control (±0.1℃) and eight-stage program ,which enhance compound separation and signal detection .
Safety Rationale: 2-chloroethanol, a toxic byproduct of EO sterilization, was previously unregulated but now falls under strict monitoring due to its potential health hazards . For manufacturers using EO sterilization, this requires validated residue removal processes; conversely, enterprises like Kailai Capsule, which avoid EO sterilization entirely, gain a competitive edge by eliminating related testing needs .